Menu ×


Qualitative Platelet Disorders Treatment Market Segmentation by Treatment (Platelet Transfusion, Hormonal Therapy, Anti-fibrinolytic Medications, Genetic Counselling, and Others); and by End-User (Hospital, Ambulatory Surgical Center, Specialty Clinics, and Others) – Global Demand Analysis & Opportunity Outlook 2030

  • Text Size:

Extensive insights into the Growth of Qualitative Platelet Disorders Treatment Market amidst COVID-19

Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.

Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.

We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.

In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months.                                                         Request Insights

Read More


  • June, 2021: Novartis AG to collaborate with Hewlett Packard Enterprise to address global health challenges. Novartis is the leading pharmaceutical company distributing drugs over the years.

  • April 2021: Merck Sharp & Dohme Corp. announced the complete acquisition of Pandion Therapeutics. After this acquisition, Pandion Therapeutics became a wholly-owned subsidiary of Merck Sharp & Dohme Corp.

Global Qualitative Platelet Disorders Treatment Market Highlights Over 2022 - 2030

The global qualitative platelet disorders treatment market is estimated to garner a notable revenue by growing at a robust CAGR over the forecast period, i.e., 2022 – 2030. Qualitative platelet disorder (QPD), also known as, Glanzmann thrombasthenia, is an autosomal recessive genetic disorder, in which platelets are unable to form proper clots due to the poor quality of platelets. The growth of the market can be attributed to the growing incidences of QPD across the globe. According to the National Organization of Rare Diseases (NORD), approximately 500 cases of QPD are reported every year, however, more than half of the cases go unreported. The symptoms of this disorder are noticeable from birth or very early in life, and leading a normal life is impossible for the patient. This is why, the demand for a permanent cure is surging across the globe, which is estimated to further boost the market growth. Moreover, the growing investment in the research and development activities in the healthcare sector is estimated to boost the market growth.

The market is segmented by treatment into platelet transfusion, hormonal therapy, anti-fibrinolytic medications, genetic counselling, and others, out of which, the genetic counselling segment is anticipated to hold the largest share in the global qualitative platelet disorders treatment market as this is the only method to avoid QPD transmission through generations. As there is no permanent cure for this, prevention of the disorder is the best possible solution, and government agencies across the world are trying to spread awareness regarding the prevention of QPD. CLICK TO DOWNLOAD SAMPLE REPORT

Major Macro-Economic Indicators Impacting the Market Growth

Healthcare Expenditure per Capita

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Global Qualitative Platelet Disorders Treatment Market Regional Synopsis

Regionally, the global qualitative platelet disorders treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in Middle East & Africa region is estimated to witness noteworthy growth over the forecast period owing to the higher prevalence of qualitative platelet disorder. QPD is a genetic disease, which is why, it is more common in communities that practice intermarriage. This is estimated to boost the growth of the regional market.

The market in the North America region is anticipated to gain the largest market share throughout the forecast period on account of high healthcare expenditure, and presence of major pharmaceutical companies in the region manufacturing the drugs to treat QPD. According to the statistics by the World Bank, in 2018, North America spent USD 10,050.516 for the healthcare of every individual.

Qualitative Platelet Disorders Treatment Market Share, (in %), By RegionThe global qualitative platelet disorders treatment market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth Market Players Analysis & Opportunity Outlook
  • Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth Market Players Analysis & Opportunity Outlook

Market Segmentation

Our in-depth analysis of the global qualitative platelet disorders treatment market includes the following segments:

By Treatment

  • Platelet Transfusion
  • Hormonal Therapy
  • Anti-fibrinolytic Medications
  • Genetic Counselling
  • Others

By End-User

  • Hospital
  • Ambulatory Surgical Center
  • Specialty Clinics
  • Others

Growth Drivers

  • Increasing Prevalence of QPD
  • Growing Investment in Medical R&D Activities


  • Lack of Access to Proper Treatment in Middle- and Low-Income Countries
  • High Cost of Treatment

Top Featured Companies Dominating the Market

  • Pfizer, Inc.
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis 
  • Merck & Co., Inc.
  • Siemens Healthcare GmbH
  • Boehringer Ingelheim International GmbH
  • Johnson & Johnson Services, Inc.
  • Baxter International, Inc.
  • Novartis AG
  • Abbott Laboratories
  • Sanofi-aventis Groupe
  • AbbVie Inc.


Related Reports

Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved